Patents by Inventor Robert Lanza

Robert Lanza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8796021
    Abstract: The present invention relates generally to the field of somatic cell nuclear transfer (SCNT) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: August 5, 2014
    Assignee: Advanced Cell Technology, Inc.
    Inventors: Robert Lanza, Young Chung
  • Patent number: 8753884
    Abstract: An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: June 17, 2014
    Assignee: Advanced Cell Technology
    Inventors: Jose Cibelli, Michael D. West, Robert Lanza
  • Patent number: 8742200
    Abstract: This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: June 3, 2014
    Assignee: Advanced Cell Technology, Inc.
    Inventors: Young Gie Chung, Robert Lanza, Irina V. Klimanskaya
  • Publication number: 20140072537
    Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
    Type: Application
    Filed: May 30, 2013
    Publication date: March 13, 2014
    Inventors: Erin Anne KIMBREL, Robert LANZA, Jianlin CHU, Nicholas Arthur KOURIS
  • Patent number: 8642328
    Abstract: This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: February 4, 2014
    Assignee: Advanced Cell Technology, Inc.
    Inventors: Robert Lanza, Young Chung
  • Publication number: 20130302286
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: April 8, 2013
    Publication date: November 14, 2013
    Inventors: Irina V. KLIMANSKAYA, Robert LANZA
  • Publication number: 20130295056
    Abstract: Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 7, 2013
    Inventor: Robert LANZA
  • Publication number: 20130058900
    Abstract: The invention is concerned with producing differentiated cells, tissues and organs from pluripotent and mutlipotent cells. The methods of the invention are particularly useful for producing differentiated cells from pluripotent cells wherein communication between the cells of more than one embryonic germ layer or more than one organ system are required for development along a specific cell lineage. The invention methods are effected by in vivo or in vitro culturing of embryonic and developing or developed allogeneic or xenogeneic cells.
    Type: Application
    Filed: March 28, 2012
    Publication date: March 7, 2013
    Inventors: Robert Lanza, Michael West
  • Publication number: 20130022680
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: May 22, 2012
    Publication date: January 24, 2013
    Inventors: Irina V. Klimanskaya, Robert Lanza
  • Publication number: 20120246746
    Abstract: This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning. Also encompassed are methods for determining the effect on immune compatibility of expressed transgenes and other genetic manipulations of the engineered cells and tissues.
    Type: Application
    Filed: May 16, 2011
    Publication date: September 27, 2012
    Inventors: Robert Lanza, Michael West
  • Publication number: 20120196769
    Abstract: This invention relates to methods for rejuvenating normal somatic cells and for making normal somatic cells of a different type having the same genotype as a normal somatic cell of interest. These cells have particular application in cell and tissue transplantation. Also encompassed are methods of re-cloning cloned animals, particularly methods where the offspring of cloned mammals are designed to be genetically altered in comparison to their cloned parent, e.g., that are “hyper-young.” These animals should be healthier and possess desirable properties relative to their cloned parent. Also included are methods for activating endogenous telomerase, EPC-1 activity, and or the ALT pathway and/or extending the life-span of a normal somatic cell, and other genes associated with cell aging and proliferation capacity.
    Type: Application
    Filed: December 23, 2011
    Publication date: August 2, 2012
    Inventors: Michael D. West, Robert Lanza, Jose Cibelil
  • Publication number: 20120184035
    Abstract: Methods and compositions are provided for reprogramming cells. In an exemplary embodiment, fibroblasts are reprogrammed to adopt a skeletal, cardiac, or smooth muscle cell fate. Cell and tissue therapies using said methods and compositions are also disclosed.
    Type: Application
    Filed: January 13, 2011
    Publication date: July 19, 2012
    Inventors: Sadhana Agarwal, Katerine L. Holton, Robert Lanza
  • Publication number: 20120027731
    Abstract: Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications.
    Type: Application
    Filed: July 26, 2011
    Publication date: February 2, 2012
    Applicant: ADVANCED CELL TECHNOLOGY
    Inventors: Robert Lanza, Shi-Jiang Lu
  • Publication number: 20110286978
    Abstract: The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells.
    Type: Application
    Filed: May 25, 2010
    Publication date: November 24, 2011
    Inventors: Irina V. Klimanskaya, Shi-Jiang Lu, Robert Lanza, Michael D. West, Karen B. Chapman, Roy Geoffrey Sargent, Raymond Page, Tanja Dominko, Christopher Malcuit
  • Publication number: 20110268709
    Abstract: Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy.
    Type: Application
    Filed: February 1, 2011
    Publication date: November 3, 2011
    Inventor: Robert Lanza
  • Patent number: 8017393
    Abstract: Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: September 13, 2011
    Assignee: Advanced Cell Technology
    Inventors: Robert Lanza, Shi-Jiang Lu
  • Publication number: 20110183415
    Abstract: This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.
    Type: Application
    Filed: January 11, 2011
    Publication date: July 28, 2011
    Inventors: Young Gie Chung, Robert Lanza, Irina V. Klimanskaya
  • Publication number: 20110171185
    Abstract: The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells.
    Type: Application
    Filed: February 4, 2010
    Publication date: July 14, 2011
    Inventors: IRINA V. KLIMANSKAYA, SHI-JIANG LU, ROBERT LANZA, MICHAEL D. WEST, KAREN B. CHAPMAN, ROY GEOFFREY SARGENT, RAYMOND PAGE, TANJA DOMINKO, CHRISTOPHER MALCUIT
  • Publication number: 20110150842
    Abstract: This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.
    Type: Application
    Filed: October 15, 2010
    Publication date: June 23, 2011
    Inventors: Robert Lanza, Young Chung
  • Publication number: 20110117063
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: August 17, 2010
    Publication date: May 19, 2011
    Applicant: Advanced Cell Technology, Inc.
    Inventors: Irina V. Klimanskaya, Robert Lanza